A trial comparing NNC0148-0287 C (insulin 287) versus insulin glargine U100, both in combination with metformin, with or without DPP4 inhibitors and with or without SGLT2 inhibitors, in basal insulin treated subjects with type 2 diabetes mellitus
Latest Information Update: 12 Dec 2022
At a glance
- Drugs Insulin icodec (Primary) ; Dipeptidyl peptidase 4 inhibitors; Insulin glargine; Metformin; Sodium-glucose transporter 2 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LAI287
- Sponsors Novo Nordisk
- 29 Jun 2021 Results from NCT03951805 and NCT03922750; comapring CGM-derived hypoglycemic episode duration between icodec and IGlar U100 in insulin-naive and insulin-experienced patients with Type-2-diabetes-mellitus, presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 29 Jun 2021 Results of a post hoc analysis comparing the time in range, time above range and and below range for icodec (LD and no loading dose - NLD) vs IGlar U100 throughout the 16-week period presented at the 81st Annual Scientific Sessions of the American Diabetes Association
- 19 Apr 2021 Results published in the Diabetes Care